Amylyx Pharmaceuticals, Inc.
AMLX
株式のランク
#4500
Amylyx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical... Amylyx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, primarily focused on creating therapies for amyotrophic lateral sclerosis (ALS) and various other neurodegenerative conditions. A key asset in its developmental pipeline is AMX0035, a proprietary dual UPR-Bax apoptosis inhibitor. This compound, which integrates sodium phenylbutyrate and taurursodiol, is under investigation for treating ALS, and its application is also being explored for other neurodegenerative diseases. The company was established in 2013 and is based in Cambridge, Massachusetts.
株価
$27.25
時価総額
$3.42B
変化（1日）
3.45%
変化（1年）
82.27%
国
US
取引 Amylyx Pharmaceuticals, Inc. (AMLX)
カテゴリー
Healthcare
Amylyx Pharmaceuticals, Inc.（AMLX）の配当履歴
Amylyx Pharmaceuticals, Inc.（証券コード：AMLX）は合計で3回の配当を行いました。
すべての配当の合計（株式分割調整済み）は：$1.02
配当利回り（TTM）：0
すべての配当の合計（株式分割調整済み）は：$1.02
配当利回り（TTM）：0
2017から2026までのAmylyx Pharmaceuticals, Inc.（AMLX）の配当履歴
年間配当支払い
| 年 | 配当（株式分割調整済み） | 変化 |
|---|---|---|
| 2026 (TTM) | $0.42 | 0.00% |
| 2018 | $0.42 | -30.00% |
| 2017 | $0.6 | 0.00% |
すべての配当支払いの一覧
| 年 | 配当 | 変化 |
|---|---|---|
| 2026 (TTM) | $0.42 | 0.00% |
| 2018 | $0.42 | -30.00% |
| 2017 | $0.6 | 0.00% |
同業他社や競合企業の配当履歴
| 企業 | 配当支払い回数 | 国 |
|---|---|---|
| 0.00% |
US
|
|
| 0.00% |
US
|
|
| 64.00% |
AU
|
|
| 0.00% |
CH
|
|
| 0.00% |
NL
|
